MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of September.
The conference presentation schedule is as follows: |
||
Bank of America Merrill Lynch Global Healthcare Conference |
||
Presented by: Timothy Morris, chief financial officer |
||
September 16, 2010 at 2:30 p.m. BST |
||
Bank of America Merrill Lynch Financial Centre, London, UK |
||
Stifel Nicolaus 2010 Healthcare Conference |
||
Presented by: Dr. Wesley Day, vice president, clinical development |
||
September 17, 2010 at 9:45 a.m. EDT |
||
Four Seasons, Boston, MA |
||
UBS Global Life Sciences Conference |
||
Presented by: Timothy Morris, chief financial officer |
||
September 22, 2010 at 12:30 p.m. EDT |
||
The Grand Hyatt, New York, NY |
||
The Fifth Annual JMP Securities Healthcare Conference |
||
Presented by: Timothy Morris, chief financial officer |
||
September 28, 2010 at 8:30 a.m. EDT |
||
The Palace Hotel, New York, NY |
||
A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
CONTACT: |
|||
VIVUS, Inc. |
Investor Relations: |
The Trout Group |
|
Timothy E. Morris |
Brian Korb |
||
Chief Financial Officer |
|||
650-934-5200 |
646-378-2923 |
||
Media Relations: |
GolinHarris |
||
Susan Brophy |
|||
312-729-4359 |
|||
SOURCE VIVUS, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article